Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics in Surgery ›› 2017, Vol. 17 ›› Issue (02): 198-201.DOI: 10.3969/j.issn.1009-976X.2017.02.016

Previous Articles     Next Articles

Effect of postoperative adjuvant chemotherapy on prognosis of elderly breast cancer

WANG Yongnan ,LI Wenping ,YU Haiyun ,WAN Jian   

  • Contact: LI Wenping

老年乳腺癌术后辅助化疗对预后的影响

王永南 李文萍 于海云 万舰   

  1. 广东省妇幼保健院
  • 通讯作者: 李文萍

Abstract:

  Objective To explore the effect of postoperative adjuvant chemotherapy on progno? sis of elderly breast cancer. Methods The data of 80 patients with breast cancer who were hospitalized for ~A ≥65 years of age from Jan. 2003 to Dec. 2013 were analyzed. Of 80 cases47 cases received adjuvant chemotherapy 33 cases did not received adjuvant chemotherapy. The clinicopathological features and clinical treatment characteristics were analyzed. Results Compared with patients who not received postoperative adjuvant chemotherapy patients received adjuvant chemotherapy were younger P=0.005),with fewer comorbidities P=0.040),higher rates of axillary lymph node metastasis P< 0.001),more the rate of ER/PR negativeP=0.029),more the rate of receiving radiotherapyP=0.005. There were no significant differences in tumor histological grade tumor sizeHER2 expressionoperation and endocrine therapyP>0.05. The median follow?up 73 monthsbetween adjuvant chemotherapy group and non?adjuvant chemotherapy group in which disease?free survival DFS had no signifi? cant difference 78.7% vs 90.9% P=0.147),overall survivalOSalso was not significantly different83.0% vs 93.9%P=0.098. Conclusions The benefit for elderly patients with postoperative adjuvant chemotherapy for breast cancer is not obvious. But for those in younger less complications asso? ciated with axillary lymph node metastasis ER/PR negativethe patients should be comprehensively as? sessed for the tolerance and benefit before postoperative adjuvant chemotherapy.

Key words: aged, adjuvant chemotherapy, breast cancer

摘要:

目的 探讨老年乳腺癌的术后辅助化疗对预后的影响。方法 收集80例Ⅰ~Ⅲ期≥65岁乳腺癌患者的资料,其中接受辅助化疗有47例,未接受辅助化疗有33例,分析两组的临床病理特点和预后特征。结果 与未接受术后辅助化疗的患者比较,接受辅助化疗年龄轻的患者较多(P=0.005)、伴有合并症较少(P=0.040)、腋窝淋巴结转移率高(P<0.001)、ER/PR阴性率高(P=0.029)、接受放疗概率高(P=0.005);而在肿瘤组织学分级、肿瘤大小、HER2表达、手术方式、内分泌治疗无明显区别(P>0.05)。中位随访期为73个月,辅助化疗组与未辅助化疗组相比,无病生存率(DFS)无明显区别(78.7% vs 90.9%P=0.147),总生存率(OS)也无明显区别(83.0% vs 93.9%P=0.098)。结论 老年乳腺癌患者术后辅助化疗的获益不明显,但对于年纪较轻、伴有合并症较少且伴有腋窝淋巴结转移、ER/PR阴性等高风险因素的患者,应全面综合评估患者的耐受性和获益程度选择术后辅助化疗。

关键词: 老年, 辅助化疗 , 乳腺癌

CLC Number: